Beam Therapeutics.
American healthcare company
- Reports this week
- 1
- Active events
- 0
- Connections
- 40
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.Some support2 reports
-
Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.Some support4 reports
-
Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.Some support1 report
-
Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.Speculative1 report
-
Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.Speculative1 report
-
H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.Speculative1 report
-
Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.Some support1 report
-
John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.Some support1 report
-
FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.Some support2 reports
-
Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Beam Therapeutics this week
News at the entities that move Beam Therapeutics most-
Cathie Wood StructuralCathie Wood bought CoreWeave during a selloff, while Goldman Sachs upgraded the company to Buy and Nvidia remains a major shareholder.Moves Beam Therapeutics
-
FDA StructuralClene Inc. submitted an NDA to the FDA seeking accelerated approval while trading on the Nasdaq exchange.Moves Beam Therapeutics
-
Ark Invest TransactionalArk Invest, led by Cathie Wood, is buying shares of Meta ahead of its earnings report.Moves Beam Therapeutics
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Beam Therapeutics
-
William P. Blair TransactionalJefferies Financial Group initiated coverage of Suja Life, Inc., providing a buy rating and price objective as of July 18, 2026.Moves Beam Therapeutics
-
Bank of America Mentioned togetherThe Office of the Comptroller of the Currency and U.S. Treasury fined Bank of America for reporting and compliance failures.Moves Beam Therapeutics
Connections
The 14 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cathie Wood Structural
Cathie Wood holds and continues to acquire shares in Beam Therapeutics.
-
FDA Structural
The FDA formally regulates Beam Therapeutics and grants critical designations and clearances for its drug candidates.
-
William P. Blair Transactional
Analyst William Blair upgraded shares of Beam Therapeutics to strong-buy.
-
Ark Invest Transactional
Ark Invest is actively purchasing or increasing its investment stake in Beam Therapeutics.
-
CRISPR Therapeutics Operational
Both companies are actively competing in the gene-editing space, developing therapies for blood disorders.
-
SEC Structural
Beam Therapeutics is subject to ongoing regulatory oversight and disclosure requirements mandated by the SEC.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports financial data, including consensus ratings and price targets, for Beam Therapeutics.
-
Amy Simon Structural
Amy Simon is identified as an insider of Beam Therapeutics, evidenced by the sale of company stock.
Show all 14 connections
-
Ark Mentioned together
Ark funds are observed tracking Beam Therapeutics stock as part of their investment strategy.
-
Bank of America Mentioned together
Bank of America provides financial ratings and price targets for Beam Therapeutics.
-
Citigroup Mentioned together
Citigroup provided financial analysis, lifting its price objective for Beam Therapeutics.
-
Wedbush Securities Mentioned together
Wedbush Securities provides investment ratings and coverage for Beam Therapeutics.
-
Cambridge Shared context
Beam Therapeutics is headquartered in Cambridge, Massachusetts.
-
BioTech Mentioned together
The single snapshot only describes Beam Therapeutics as a healthcare company and provides no evidence of a relationship with BioTech.
History
Events by the month they beganOctober 2026
2 eventsJuly 2026
4 events- Redmile Group LLC trimmed its position in Beam Therapeutics.
- Cathie Wood has acquired and continues to acquire shares of Beam Therapeutics.
- Citigroup lifted its price objective and gave a buy rating for Beam Therapeutics, while Bank of America restated its buy rating and set a new price target.
- Beam Therapeutics and Prime Medicine are competing for market share in the AATD gene-editing space, with an arbitration ruling favoring Prime's program.
June 2026
7 events- Sana Biotechnology, based in Seattle, presented promising cell therapy data on July 3, 2025, involving a gene editing system and potential benefits from Trump-era tariffs.
- Ashish Gupta, an associate professor at the University of Minnesota, was an investigator in the BEACON trial as of July 3, 2025.
- H.C. Wainwright reiterated a Buy rating for Beam Therapeutics on July 6, 2025.
- Market expects earnings based on consensus outlook for Beam Therapeutics, announced on July 29, 2025.
- John Evans was appointed chief executive officer of Beam Therapeutics on August 5, 2025.
- FDA granted RMAT designation to Beam Therapeutics' drug candidate BEAM-101.
- Beam Therapeutics participated in investor conferences held in Boston on August 25, 2025.